Shares of oncology therapeutics company CytomX Therapeutics, Inc. were trading higher after hours Tuesday following the company’s release of fourth-quarter financial results and a business update.
At 5:48 p.m. EST, the company’s shares were trading 11.58% higher at $3.95 a share. The stock finished the day’s regular session with a 7.57% loss, closing at $3.54 a share.
Earlier Tuesday, the stock touched a 52-week low of $3.52 a share.
After the bell, CytomX reported revenue of $19.7 million, up from the $16.4 million reported in the year-ago period.
The company also said a first-in-human study of CX-904 in advanced solid tumors will be initiated in first half of this year. CytomX also said it will continue patient enrollment in the expansion phase of the Phase 2 study of CX-2029 to treat cancer.